Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
2
Frequently Asked Questions
What is Market Cap of Tharimmune Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Tharimmune Inc market cap is $4.03M.
What is the 52-week high for Tharimmune Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Tharimmune Inc 52 week high is $163.09 as of June 05, 2024.
What is the 52-week low for Tharimmune Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Tharimmune Inc 52 week low is $4.15 as of June 05, 2024.
What is Tharimmune Inc stock price today?
Tharimmune Inc stock price today is $5.15.
What was Tharimmune Inc stock price yesterday?
Tharimmune Inc stock price yesterday was $5.12.
What is the PE ratio of Tharimmune Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Tharimmune Inc’s P/E ratio is -0.05.
What is the Price-to-Book ratio of Tharimmune Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Tharimmune Inc P/B ratio is 0.5710.
What is Tharimmune Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Tharimmune Inc's EBITDA is 0.34.
What is the 50-day moving average of Tharimmune Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Tharimmune Inc 50-day moving average is $5.72.